Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Operating Expenses: 2022-2025

Historic Operating Expenses for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to $55.5 million.

  • NewAmsterdam Pharma Co N.V's Operating Expenses rose 2.54% to $55.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $238.2 million, marking a year-over-year increase of 9.39%. This contributed to the annual value of $221.9 million for FY2024, which is 12.58% up from last year.
  • Per NewAmsterdam Pharma Co N.V's latest filing, its Operating Expenses stood at $55.5 million for Q3 2025, which was up 1.30% from $54.8 million recorded in Q2 2025.
  • Over the past 5 years, NewAmsterdam Pharma Co N.V's Operating Expenses peaked at $71.9 million during Q1 2025, and registered a low of -$31.2 billion during Q4 2022.
  • Its 3-year average for Operating Expenses is $54.6 million, with a median of $54.8 million in 2025.
  • Per our database at Business Quant, NewAmsterdam Pharma Co N.V's Operating Expenses skyrocketed by 100.17% in 2023 and then decreased by 0.13% in 2025.
  • NewAmsterdam Pharma Co N.V's Operating Expenses (Quarterly) stood at -$31.2 billion in 2022, then skyrocketed by 100.17% to $51.9 million in 2023, then grew by 7.95% to $56.0 million in 2024, then increased by 2.54% to $55.5 million in 2025.
  • Its last three reported values are $55.5 million in Q3 2025, $54.8 million for Q2 2025, and $71.9 million during Q1 2025.